ClinicalTrials.gg
CompletedNCT01564862Updated Feb 5, 2015Results posted

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

A Phase 2 interventional study of vortioxetine (Lu AA21004) and Duloxetine in Depressive Disorder, Major, sponsored by Takeda. Completed at 92 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-05.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
13th of 54
602 · median 413
Started
2012
with 2 others
Phase 2
6 of 54
none open now
Registered
23rd of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 13th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 2, and was the 23rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.

Read the detailed description

Lu AA21004 is under codevelopment by Takeda Global Research \& Development Center, Inc. and H. Lundbeck A/S for the treatment of MDD.

This study will consist of a screening period within 10 days of the Baseline Visit followed by an 8-week double-blind treatment period and a one-week taper down period.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant has recurrent MDD as the primary diagnosis according to , Fourth Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.3x). The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI) V6.0.0.
  4. The participant has received prescribed treatment for a previous episode of depression.
  5. The participant has a MADRS total score ≥26 at both the screening and baseline visits.
  6. Participant reports subjective cognitive dysfunction (such as difficulty concentrating, slow thinking, and difficulty in learning new things or remembering things).
  7. The reported duration of the current major depressive episode (MDE) is at least 3 months
  8. The participant is a man or woman between 18 and 65 years old, inclusive.
  9. A female participant of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of the informed consent throughout the duration of the study and for 30 days after completion of the study.

Exclusion criteria

Exclusion Criteria:

  1. The participant has previously participated in this study.
  2. The participant has a history of severe drug allergy or , or known hypersensitivity to any of the of the medicinal product (IMP).
  3. The participant has known hypersensitivity to duloxetine.
  4. The participant has hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency.
  5. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant has a score ≥70 on the DSST (numbers correct) at the Baseline Visit.
  7. The participant is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  8. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
  9. The participant has 1 or more of the following:

    1. Any current psychiatric disorder other than MDD as defined in the (as assessed by the MINI Version 6.0.0).
    2. Current or history of attention deficit hyperactivity disorder (ADHD), pervasive developmental disorder, manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    3. Current diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least 2 years prior to Screening. (Participant must also have negative urine drug screen prior to Baseline).
    4. Presence or history of a neurological disorder (including epilepsy).
    5. Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, etc).
    6. Any DSM-IV Axis II disorder that might compromise the study.
  10. The participant has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.
  11. The participant has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  12. The participant is diagnosed with reading disability (dyslexia).
  13. The participant has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
  14. The participant, in the opinion of the investigator, poses a risk of harm to others.
  15. The participant has initiated formal cognitive or behavioral therapy, systemic psychotherapy within less than 6 months of study screening, or has plans to initiate such therapy during the study.
  16. The participant has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
  17. The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the recommended dose.
  18. The participant has a history of moderate or severe head trauma (for example, loss of consciousness for more than 1 hour) or other neurological disorders or systemic medical diseases that are, in the opinion of the investigator, likely to affect central nervous system functioning.
  19. The participant has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of investigational drug. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
  20. The participant has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.

    Note: For the purposes of this protocol, the following conditions are considered unstable due to the potential impact on assessment of MDD response and/or cognitive status: pain disorders, chronic fatigue syndrome, fibromyalgia, obstructive sleep apnea, and known cases of , , and

  21. The participant has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  22. The participant is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study evaluation period as specified in the Excluded Medications Section.
  23. The participant has received any investigational compound \<30 days before Screening or 5 half-lives prior to Screening.
  24. The participant has clinically significant abnormal vital signs as determined by the investigator.
  25. The subject has thyroid stimulating hormone (TSH) outside the normal range at the Screening Visit.

    Note: If TSH value is outside the normal range, a free T4 will be obtained. Subjects who have elevated TSH but normal T4 (i.e. subclinical hypothyroidism) will be excluded. For subjects who are on thyroid hormone replacement therapy, a lower TSH with normal T4, are eligible to participate in the study only if there are no clinical symptoms of hypothyroidism .

  26. The participant has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:

    1. A serum creatinine value >1.5 times the (×ULN).
    2. A total serum total value >1.5×ULN.
    3. A serum (ALT) or aspartate aminotransferase (AST) value >2×ULN.
  27. The participant has an abnormal (ECG) as determined by the central reader and confirmed as clinically significant by the investigator.
  28. The participant has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  29. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  30. The participant has been previously exposed to LuAA21004 compound.
  31. The participant has a history of lack of response to previous adequate treatment with duloxetine.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
602 participants (actual)

Study arms

  • Experimental
    Vortioxetine (Lu AA21004) QD

    Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.

    Drug: vortioxetine (Lu AA21004)

  • Active comparator
    Duloxetine QD

    Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.

    Drug: Duloxetine

  • Placebo comparator
    Placebo QD

    Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)

    The DSST assesses relative contributions of speed, memory, executive function and visual scanning. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function. An Analysis of Covariance (ANCOVA) model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore

    PDQ is a patient-rated scale designed to subjectively assess cognitive dysfunction, comprising four 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization for a total possible score of 0 to 40. The subscale Attention/Concentration is the sum of items 1, 5, 9, 13, and 17 with a range of 0-20; while the subscale Planning/Organization is the sum of items 4, 8, 12, 16, and 20 with the score range of 0 to 20. The scores of the subscales Attention/Concentration and Planning/Organization were summed. Higher scores reflect greater participant-perceived cognitive dysfunction in the domains identified. A decrease in score represents an improvement in subjective cognitive function in the domains identified. A Mixed Model Repeated Measures (MMRM) model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

    Time frame: Baseline and Week 8

  2. Clinical Global Impressions-Improvement (CGI-I) Score at Week 8

    The CGI-I assesses the clinician's impression of the subject's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change relative to baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. A MMRM model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

    Time frame: Baseline, Week 8

  3. Change From Baseline to Week 8 in the Trail Making Test (TMT-A)

    The TMT is a two-part cognitive test. TMT-A assesses cognitive processing speed and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower scores represent better speed of processing. A decrease in score over the study represents an improvement in speed in processing. An ANCOVA model was used with treatment and center as fixed factors and the baseline value as a covariate.

    Time frame: Baseline and Week 8

  4. Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)

    The TMT is a two-part cognitive test. TMT-B assesses executive functioning and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower score for TMT-B represents better executive function. A decrease in score over the study represents an improvement in executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  5. Change in Time From Baseline to Week 8 in the Stroop Test

    The STROOP test assesses the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises of 2 sheets with 50 words each, up to 50 correct responses for each of the congruent and incongruent Stroop tests. Participants have 4 minutes to name the ink color of each word. Lower time to complete the test indicates better performance. Higher number of correct responses indicates better responses. A decrease in the time to complete the tests and an increase in the number of correct responses both indicate improvement over the course of the study. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  6. Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)

    The GMLT measures executive functioning and spatial problem solving. Participants learn a hidden pathway through a maze of 10 x 10 grid of tiles on a computer touch screen using step-by-step guess, with trial and error feedback after each step. Once the pathway is learned, participants repeat the same pathway four more times. It usually takes 5-6 minutes to administer this test. Lower score equals better performance. A decrease in score over the course of the study indicates improved executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  7. Change From Baseline to Week 8 in the Detection Task (DT)

    The DT is a computerized test that measures simple reaction time and psychomotor speed. The task requires participants to respond by pressing a "yes" button as soon as an onscreen playing card is turned over and is red, and by pressing a "no" button if the card is not red. It takes 2 minutes to be administered. There is no minimum or maximum scores since it is a time-based assessment. Lower score equals better performance. A decrease in score over the course of the study indicates improved speed of processing and psychomotor function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  8. Change From Baseline to Week 8 in the Identification Task (IT)

    The IT measured choice reaction time: the participant pressed a "yes" button whenever an onscreen playing card turned face up and was red, or a "no" button if the card was not red. The IT took on average 2 minutes to complete. Lower scores equal better performance. A decrease in score over the course of the study indicates improved visual attention/vigilance. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  9. Change From Baseline to Week 8 in the One-Back Task

    The One-Back test measures the cognitive domain of attention and working memory through yes or no responses to 30 trials. The task requires participants to report when a stimulus item presented serially is the same as an item one step back from the item at hand for a total correct responses 0 to 100. It usually takes 2-3 minutes to be administered. Higher scores equal better performance. An increase in score over the course of the study indicates improved attention/working memory. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  10. Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression

    Improvement of Cognitive Dysfunction is determined using the change from Baseline to Week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score and the Digital Symbol Substitution Test (DSST) total number of correct symbols. The MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression). The DSST assesses relative contributions of speed, memory, executive function and visual scanning. The proportion of direct effect from treatment = DSST difference / (DSST difference + coefficient\*MADRS difference).

    Time frame: Baseline and Week 8

  11. Change From Baseline to Week 8 in the MADRS Total Score

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 1, Week 4 and Week 8

  12. Percentage of Participants With MADRS Response at Week 8

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Response was defined as a ≥50% decrease in MADRS Total Score from Baseline.

    Time frame: Baseline and Week 8

  13. Percentage of Participants in MADRS Remission at Week 8

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Remission was defined as a MADRS total score ≤10.

    Time frame: Week 8

  14. Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score

    The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill). A MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors was used for analyses.

    Time frame: Baseline, Week 1, Week 4 and Week 8

07

Results

Posted Feb 5, 2015

Participant flow

Participants took part in the study at 80 investigative sites in Bulgaria, Finland, Germany, Poland, Russia Federation, Ukraine.and the United States from 09 April 2012 to 05 February 2014

Participant flow — Overall Study
MilestoneVortioxetine (Lu AA21004)DuloxetinePlacebo
Started198210194
Received treatment196207191
Completed168176164
Not completed303430
Withdrew: Pretreatment event or adverse event6126
Withdrew: Major protocol deviation334
Withdrew: Lost to follow-up1086
Withdrew: Voluntary withdrawal968
Withdrew: Lack of efficacy156
Withdrew: Other reason(s)100

Outcome measures

PrimaryChange From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)

The DSST assesses relative contributions of speed, memory, executive function and visual scanning. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function. An Analysis of Covariance (ANCOVA) model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Correct symbols
Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)
Correct symbolsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)4.60 ± 0.5304.06 ± 0.5112.85 ± 0.542
Statistical analysis
  • Vortioxetine (Lu AA21004) vs Placebo · ANCOVA · p = 0.019 (P-value was from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.) · Ls mean difference: 1.75 · 95% CI 0.28 to 3.21
  • Duloxetine vs Placebo · ANCOVA · p = 0.099 (P-value was from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.) · Ls mean difference: 1.21 · 95% CI -0.23 to 2.65
  • Vortioxetine (Lu AA21004) vs Duloxetine · ANCOVA · p = 0.460 (P-value was from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.) · Ls mean difference: 0.54 · 95% CI -0.89 to 1.96
SecondaryChange From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore

PDQ is a patient-rated scale designed to subjectively assess cognitive dysfunction, comprising four 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization for a total possible score of 0 to 40. The subscale Attention/Concentration is the sum of items 1, 5, 9, 13, and 17 with a range of 0-20; while the subscale Planning/Organization is the sum of items 4, 8, 12, 16, and 20 with the score range of 0 to 20. The scores of the subscales Attention/Concentration and Planning/Organization were summed. Higher scores reflect greater participant-perceived cognitive dysfunction in the domains identified. A decrease in score represents an improvement in subjective cognitive function in the domains identified. A Mixed Model Repeated Measures (MMRM) model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore
score on a scaleVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore-8.9 ± 0.55-9.3 ± 0.53-6.3 ± 0.57
Statistical analysis
  • Vortioxetine (Lu AA21004) vs Placebo · Mixed Models Analysis · p = 0.001 (P-value was from a MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.) · Ls mean difference: -2.6 · 95% CI -4.1 to -1.0
  • Duloxetine vs Placebo · Mixed Models Analysis · p = <0.001 (P-value was from a MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.) · Ls mean difference: -3.0 · 95% CI -4.5 to -1.5
SecondaryClinical Global Impressions-Improvement (CGI-I) Score at Week 8

The CGI-I assesses the clinician's impression of the subject's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change relative to baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. A MMRM model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Clinical Global Impressions-Improvement (CGI-I) Score at Week 8
score on a scaleVortioxetine (Lu AA21004)DuloxetinePlacebo
Clinical Global Impressions-Improvement (CGI-I) Score at Week 82.349 ± 0.08522.235 ± 0.08262.639 ± 0.0872
Statistical analysis
  • Vortioxetine (Lu AA21004) vs Placebo · Mixed Models Analysis · p = 0.017 (P-value was from a MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.) · Ls mean difference: -0.290 · 95% CI -0.528 to -0.052
  • Duloxetine vs Placebo · Mixed Models Analysis · p = <0.001 (P-value was from a MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.) · Ls mean difference: -0.404 · 95% CI -0.638 to -0.169
SecondaryChange From Baseline to Week 8 in the Trail Making Test (TMT-A)

The TMT is a two-part cognitive test. TMT-A assesses cognitive processing speed and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower scores represent better speed of processing. A decrease in score over the study represents an improvement in speed in processing. An ANCOVA model was used with treatment and center as fixed factors and the baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · seconds
Change From Baseline to Week 8 in the Trail Making Test (TMT-A)
secondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Trail Making Test (TMT-A)-7.70 ± 0.980-8.06 ± 0.955-6.65 ± 1.009
SecondaryChange From Baseline to Week 8 in the Trail Making Test B (TMT-B)

The TMT is a two-part cognitive test. TMT-B assesses executive functioning and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower score for TMT-B represents better executive function. A decrease in score over the study represents an improvement in executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · seconds
Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)
secondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)-18.73 ± 2.096-14.60 ± 2.011-9.06 ± 2.101
SecondaryChange in Time From Baseline to Week 8 in the Stroop Test

The STROOP test assesses the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises of 2 sheets with 50 words each, up to 50 correct responses for each of the congruent and incongruent Stroop tests. Participants have 4 minutes to name the ink color of each word. Lower time to complete the test indicates better performance. Higher number of correct responses indicates better responses. A decrease in the time to complete the tests and an increase in the number of correct responses both indicate improvement over the course of the study. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Mean · seconds
Change in Time From Baseline to Week 8 in the Stroop Test
secondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Congruent (n=174,187,167)-3.30 ± 1.086-4.54 ± 1.044-4.37 ± 1.105
Incongruent (n=172,186,166)-8.17 ± 1.560-9.83 ± 1.498-8.11 ± 1.586
SecondaryChange From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)

The GMLT measures executive functioning and spatial problem solving. Participants learn a hidden pathway through a maze of 10 x 10 grid of tiles on a computer touch screen using step-by-step guess, with trial and error feedback after each step. Once the pathway is learned, participants repeat the same pathway four more times. It usually takes 5-6 minutes to administer this test. Lower score equals better performance. A decrease in score over the course of the study indicates improved executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Errors
Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)
ErrorsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)-5.43 ± 1.355-5.16 ± 1.314-3.49 ± 1.397
SecondaryChange From Baseline to Week 8 in the Detection Task (DT)

The DT is a computerized test that measures simple reaction time and psychomotor speed. The task requires participants to respond by pressing a "yes" button as soon as an onscreen playing card is turned over and is red, and by pressing a "no" button if the card is not red. It takes 2 minutes to be administered. There is no minimum or maximum scores since it is a time-based assessment. Lower score equals better performance. A decrease in score over the course of the study indicates improved speed of processing and psychomotor function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Log10 milliseconds
Change From Baseline to Week 8 in the Detection Task (DT)
Log10 millisecondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Detection Task (DT)-0.050 ± 0.0080-0.039 ± 0.0078-0.033 ± 0.0082
SecondaryChange From Baseline to Week 8 in the Identification Task (IT)

The IT measured choice reaction time: the participant pressed a "yes" button whenever an onscreen playing card turned face up and was red, or a "no" button if the card was not red. The IT took on average 2 minutes to complete. Lower scores equal better performance. A decrease in score over the course of the study indicates improved visual attention/vigilance. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Log10 milliseconds
Change From Baseline to Week 8 in the Identification Task (IT)
Log10 millisecondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the Identification Task (IT)-0.037 ± 0.0060-0.030 ± 0.0059-0.024 ± 0.0062
SecondaryChange From Baseline to Week 8 in the One-Back Task

The One-Back test measures the cognitive domain of attention and working memory through yes or no responses to 30 trials. The task requires participants to report when a stimulus item presented serially is the same as an item one step back from the item at hand for a total correct responses 0 to 100. It usually takes 2-3 minutes to be administered. Higher scores equal better performance. An increase in score over the course of the study indicates improved attention/working memory. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Log 10 milliseconds
Change From Baseline to Week 8 in the One-Back Task
Log 10 millisecondsVortioxetine (Lu AA21004)DuloxetinePlacebo
Change From Baseline to Week 8 in the One-Back Task-0.028 ± 0.0062-0.024 ± 0.0060-0.022 ± 0.0063
SecondaryProportion of Cognitive Dysfunction Improvement Due to Improvement of Depression

Improvement of Cognitive Dysfunction is determined using the change from Baseline to Week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score and the Digital Symbol Substitution Test (DSST) total number of correct symbols. The MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression). The DSST assesses relative contributions of speed, memory, executive function and visual scanning. The proportion of direct effect from treatment = DSST difference / (DSST difference + coefficient\*MADRS difference).

Time frame:
Baseline and Week 8
Reported as:
Number · proportion of direct effect
Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression
proportion of direct effectVortioxetine (Lu AA21004)Duloxetine
Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression75.6648.69
SecondaryChange From Baseline to Week 8 in the MADRS Total Score

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 1, Week 4 and Week 8
Reported as:
Mean · score on a scale
Change From Baseline to Week 8 in the MADRS Total Score
score on a scaleVortioxetine (Lu AA21004)DuloxetinePlacebo
Change at Week 1-3.7 ± 4.80-4.6 ± 5.29-3.4 ± 5.03
Change at Week 4-9.8 ± 6.85-11.6 ± 7.94-8.0 ± 7.98
Change at Week 8-14.3 ± 8.97-15.5 ± 9.23-12.3 ± 9.64
SecondaryPercentage of Participants With MADRS Response at Week 8

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Response was defined as a ≥50% decrease in MADRS Total Score from Baseline.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With MADRS Response at Week 8
percentage of participantsVortioxetine (Lu AA21004)DuloxetinePlacebo
Percentage of Participants With MADRS Response at Week 850.954.541.3
SecondaryPercentage of Participants in MADRS Remission at Week 8

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Remission was defined as a MADRS total score ≤10.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 8
percentage of participantsVortioxetine (Lu AA21004)DuloxetinePlacebo
Percentage of Participants in MADRS Remission at Week 830.333.721.6
SecondaryChange From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score

The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill). A MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors was used for analyses.

Time frame:
Baseline, Week 1, Week 4 and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
score on a scaleVortioxetine (Lu AA21004)DuloxetinePlacebo
Change from Baseline at Week 1 (n=174, 187,167)-0.289 ± 0.0426-0.353 ± 0.0410-0.243 ± 0.0435
Change from Baseline at Week 4 (n=173,184,165)-0.951 ± 0.0678-1.170 ± 0.0656-0.617 ± 0.0693
Change from Baseline at Week 8 (n=169,179,161)-1.546 ± 0.0886-1.698 ± 0.0859-1.225 ± 0.0906

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine (Lu AA21004)—1/196 (0.5%)73/196 (37.2%)
Duloxetine—1/207 (0.5%)84/207 (40.6%)
Placebo—2/191 (1%)41/191 (21.5%)
Most frequent serious events
Most frequent serious events
EventVortioxetine (Lu AA21004)DuloxetinePlacebo
Acute myocardial infarctionCardiac disorders0/1960/2071/191
DepressionPsychiatric disorders0/1960/2071/191
Suicide attemptPsychiatric disorders1/1960/2070/191
Craniocerebral injuryInjury, poisoning and procedural complications0/1961/2070/191
Subdural haematomaInjury, poisoning and procedural complications0/1961/2070/191
Most frequent other events
Most frequent other events
EventVortioxetine (Lu AA21004)DuloxetinePlacebo
NauseaGastrointestinal disorders40/19643/2078/191
HeadacheNervous system disorders20/19624/20716/191
Dry mouthGastrointestinal disorders6/19616/2079/191
Decreased appetiteMetabolism and nutrition disorders3/19612/2071/191
NasopharyngitisInfections and infestations7/1968/20711/191
DiarrhoeaGastrointestinal disorders11/1966/2075/191
DizzinessNervous system disorders6/19611/2075/191

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Mean44.2 ± 12.2145.7 ± 11.4645.0 ± 12.0745.0 ± 11.90
Age, Customized
Age, Customized(participants)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
≤ 55 years158164152474
> 55 years404642128
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Female135138119392
Male637275210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Hispanic or Latino871530
Non-Hispanic and Non- Latino9010482276
Not-Specified1009997296
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Caucasian (or White, including Hispanic)169176171516
Black28272075
Asian1618
American Indian or Alaska Native0123
Height
Height(cm)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Mean168.2 ± 9.17169.7 ± 9.14169.0 ± 9.43169.0 ± 9.25
Weight
Weight(kg)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Mean81.84 ± 22.06881.68 ± 20.96580.96 ± 20.31681.50 ± 21.099
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vortioxetine (Lu AA21004)DuloxetinePlaceboTotal
Mean28.86 ± 7.33428.39 ± 7.31228.27 ± 6.35428.51 ± 7.018

2 further baseline measures are reported on the registry.

08

Study locations

92 sites
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Bellflower, California, United States
  • Carson, California, United States
  • Cerritos, California, United States
  • Glendale, California, United States
  • Imperial, California, United States
  • Los Angeles, California, United States
  • Norwalk, California, United States
  • Oakland, California, United States
  • Paramount, California, United States
  • San Bernardino, California, United States
  • Santa Ana, California, United States
  • Wildomar, California, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Norwalk, Connecticut, United States
  • Lauderhill, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Sanford, Florida, United States
  • St. Petersburg, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Chicago, Illinois, United States
  • Hoffman Estates, Illinois, United States
  • Naperville, Illinois, United States
  • Oak Brook, Illinois, United States
  • Skokie, Illinois, United States
  • Indianapolis, Indiana, United States
  • Prairie Village, Kansas, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Haverhill, Massachusetts, United States
  • St. Louis, Missouri, United States
  • North Platte, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Avon lake, Ohio, United States
  • Beachwood, Ohio, United States
  • Garfield Heights, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Norristown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Franklin, Tennessee, United States
  • Memphis, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • The Woodlands, Texas, United States
  • Orem, Utah, United States
  • Salt Lake City, Utah, United States
  • Kirkland, Washington, United States
  • Seattle, Washington, United States
  • Brown Deer, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • Kazanlak, Bulgaria
  • Novi Iskar, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Tzerova Koria, Bulgaria
  • Helsinki, Finland
  • Kuopio, Finland
  • Turku, Finland
  • Berlin, Germany
  • Bochum, Germany
  • Chemnitz, Germany
  • Hannover, Germany
  • Munchen, Germany
  • Schwerin, Germany
  • Westerstede, Germany
  • Wiesbaden, Germany
  • Bialystok, Poland
  • Leszno, Poland
  • Lodz, Poland
  • Torun, Poland
  • Ekaterinburg, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Saint-Petersburg, Russian Federation
  • Smolensk, Russian Federation
  • Stavropol, Russian Federation
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Luhansk, Ukraine
  • Ternopil, Ukraine
09

References and documents

Publications

  • Jacobson W, Zhong W, Nomikos GG, Christensen MC, Kurre Olsen C, Harvey PD. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. Curr Med Res Opin. 2020 Jan;36(1):117-124. doi: 10.1080/03007995.2019.1657692. Epub 2019 Aug 29. PubMed 31422713 ↗
  • Christensen MC, Sluth LB, McIntyre RS. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. J Affect Disord. 2019 Feb 15;245:508-516. doi: 10.1016/j.jad.2018.11.034. Epub 2018 Nov 5. PubMed 30439678 ↗
  • Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. J Affect Disord. 2018 Feb;227:787-794. doi: 10.1016/j.jad.2017.11.081. Epub 2017 Nov 16. PubMed 29689693 ↗
  • Keefe RSE, Nomikos G, Zhong W, Christensen MC, Jacobson W. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. Int J Neuropsychopharmacol. 2018 May 1;21(5):442-447. doi: 10.1093/ijnp/pyy020. PubMed 29546401 ↗
  • Christensen MC, Munro V. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Curr Med Res Opin. 2018 Apr;34(4):593-600. doi: 10.1080/03007995.2017.1416952. Epub 2018 Jan 16. PubMed 29235884 ↗
  • Harvey PD, Jacobson W, Zhong W, Nomikos GG, Cronquist Christensen M, Kurre Olsen C, Merikle E. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder. J Affect Disord. 2017 Apr 15;213:105-111. doi: 10.1016/j.jad.2017.02.014. Epub 2017 Feb 14. PubMed 28213121 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2012
First posted
Mar 28, 2012
Start
Apr 2012
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Feb 5, 2015
Last update
Feb 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01564862
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 28, 2012
Start date
Apr 2012
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Feb 5, 2015
Last update
Feb 5, 2015

Study contacts

Senior Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion